Q BioMed (Q BioMed) Dividend Payout Ratio : 0.00 (As of Feb. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Q BioMed Dividend Payout Ratio?

Q BioMed's dividend payout ratio for the months ended in Feb. 2023 was 0.00.

The historical rank and industry rank for Q BioMed's Dividend Payout Ratio or its related term are showing as below:

QBIO's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.435
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-27), the Dividend Yield % of Q BioMed is 0.00%.

Q BioMed's Dividends per Share for the months ended in Feb. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Q BioMed Dividend Payout Ratio Historical Data

The historical data trend for Q BioMed's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q BioMed Dividend Payout Ratio Chart

Q BioMed Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Dividend Payout Ratio

Get a 7-Day Free Trial

Q BioMed Quarterly Data
	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Q BioMed's Dividend Payout Ratio

For the Biotechnology subindustry, Q BioMed's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q BioMed's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q BioMed's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Q BioMed's Dividend Payout Ratio falls into.

Q BioMed Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Q BioMed's Dividend Payout Ratio for the fiscal year that ended in Nov. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Nov. 2022 )	/	EPS without NRI (A: Nov. 2022 )
	=	0	/	-0.072
	=	N/A

Q BioMed's Dividend Payout Ratio for the quarter that ended in Feb. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Feb. 2023 )	/	EPS without NRI (Q: Feb. 2023 )
	=	0	/	-0.02
	=	N/A

Q BioMed (OTCPK:QBIO) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Q BioMed Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Q BioMed's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Q BioMed (Q BioMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017

Website

https://www.qbiomed.com

Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.

Executives

William S Rosenstadt	director, 10 percent owner, officer: Chief Legal Officer	ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin	director, 10 percent owner, officer: Chief Executive Officer	10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci	director	501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay	10 percent owner	580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1